Aurinia Pharmace Stock Price, News & Analysis

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) is sponsoring charitable grants to expand community-focused patient navigator programs for individuals with systemic lupus erythematosus (SLE) and lupus nephritis (LN). This initiative aims to eliminate care barriers, particularly in underserved populations. Grants of up to $50,000 will be awarded to U.S.-based organizations to enhance patient education and access to treatment. In its first year, Aurinia distributed $250,000 to five programs, showing significant improvements in patient care and adherence.

Aurinia Pharmaceuticals (NASDAQ: AUPH) announced new analyses of LUPKYNIS™ (voclosporin) to be presented at the 2022 National Kidney Foundation Spring Clinical Meetings in Boston from April 6-10, 2022. The studies aim to expand the understanding of LUPKYNIS, the first FDA-approved oral therapy for lupus nephritis. Presentations will include findings on the drug's efficacy, a prospective observational registry, and improvements in disease impact. The research underscores Aurinia's commitment to autoimmune disease therapeutics.

Aurinia Pharmaceuticals (NASDAQ: AUPH) announced its executive management team's participation in two investor conferences. The Cowen 42nd Annual Virtual Healthcare Conference is scheduled for March 9, 2022, at 2:50 p.m. ET, while the Oppenheimer’s 32nd Annual Healthcare Conference will take place on March 16, 2022, at 1:20 p.m. ET. Interested parties can access the live webcasts on the Aurinia corporate website under the Investors section.

Aurinia is focused on treating serious diseases, having launched LUPKYNIS™, the first FDA-approved oral therapy for active lupus nephritis in January 2021.

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported a 60% increase in Q4 2021 net revenue to $23.4 million and a full-year revenue of $45.6 million. The company achieved notable growth in LUPKYNIS patient starts and maintained a strong cash position of $466.1 million as of December 31, 2021. For 2022, Aurinia projects net revenue guidance of $115-$135 million, driven by positive results from the AURORA 2 study. With confirmed payor coverage exceeding 90% in the U.S., Aurinia is well-positioned for ongoing progress amid a robust product launch.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) will release its fourth quarter and year-end 2021 financial results on February 28, 2021, before markets open. A conference call/webcast will be held at 8:30 am ET to discuss the results and the company's outlook for 2022. Aurinia focuses on therapies for serious diseases with high unmet needs, having launched the first FDA-approved oral treatment for active lupus nephritis in January 2021.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced its participation in the 11th Annual Leerink Global Healthcare Conference, scheduled from February 14-18, 2022. The company's corporate presentation will take place virtually on February 16, 2022, at 8 am ET. Interested participants can listen to the presentation by registering through a public link or by visiting the Investor section of Aurinia's corporate website. Aurinia is focused on developing therapies for serious diseases with high unmet medical needs, notably introducing the first FDA-approved oral therapy for active lupus nephritis in January 2021.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) announced participation in two virtual investor conferences. The H.C. Wainwright Virtual BioConnect 2022 Conference will feature an on-demand presentation from January 10 to January 13, 2022. Additionally, the J.P. Morgan 40th Annual Healthcare Conference will host a presentation on January 13, 2022, at 9:45 am EST. Interested individuals can access these presentations via the 'Investors' section on the Aurinia corporate website, which also provides further details on the company's focus in the biopharmaceutical industry.

Aurinia Pharmaceuticals (NASDAQ:AUPH) announced positive topline results from the AURORA 2 study, evaluating LUPKYNIS™ (voclosporin) for lupus nephritis treatment. The study showed a favorable risk/benefit profile and sustained efficacy over three years. Notably, the voclosporin-treated group maintained stable renal function and exhibited significant reductions in proteinuria compared to mycophenolate mofetil (MMF) and low-dose corticosteroids. Safety parameters were comparable, with no unexpected safety signals. The company will hold a conference call on December 9 at 8:30 a.m. EST.

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) will present at the 2021 Jefferies London Healthcare Conference from November 16-19, 2021. The on-demand presentation will be available starting on November 18 at 8 am GMT/3 am EST and will remain accessible until November 19 at 5 pm GMT/12 pm EST. Interested parties can access the webcast via the Aurinia corporate website's Investor section. Aurinia focuses on developing therapies for serious diseases with high unmet medical needs and has introduced the first FDA-approved oral therapy for adults with active lupus nephritis.